SBT 16th Annual Meeting
Oral Abstracts
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
Therapeutic and Specific Antitumor
Immunity Induced by IL12 and IL18 in Fibroblasts and DCs:
Preclinical Studies and Application to Patients
IL-15: Relevance in Biology
and Disease
The Laboratory and Clinical
Biology of Cancer Treatment with Tumor Reactive mAb Linked
to IL2
Preclinical and Clinical Investigation
of IL-12/Pulse IL-2
Phase I Trial of Twice-Weekly
IV rhIL-12 Plus Low-Dose SC IL-2 in Patients with Melanoma
and Renal Cell Cancer
IL-7: Emerging role in immunorestoration
and vaccination
Tumor Vaccination with Interleukin-12
and Granulocyte Macrophage-Colony Stimulating Factor-Encapsulated
Microspheres: Co-induction of Innate and Adaptive Immunity
Promotes Cure of Disseminated Disease
A Randomized Phase III Trial
of High-Dose Interleukin-2 (HD IL2) versus Subcutaneous (SC)
IL2/Interferon (IFN) in Patients with Metastatic Renal Cell
Carcinoma (RCC)
Title: Phenotypic Diversity
of Endothelial Cells is Defined by the Organ Microenvironment
The Imaging of Angiogenesis
Molecular Determinants of
the Angiogenic Switch and Tumor Progression
Endothelial Cell Gene Expression
Profiling
In vivo tumor imaging using
near infrared labeled Endostatin
Peptide-Targeting IL-12 to
avb3 Integrin Mediates Potent Antiangiogenic Activity
Signal and transcriptional
activation of proinflammatory and proangiogenic factor expression
by cancer cells as a target for biological therapy
Preclinical Strategies to
Improve Dendritic Cell-Based Tumor Vaccines
Dendritic cells as vectors
and targets for therapy
Multi-epitope Peptide Vaccines
with GMCSF and IL2: CTL Responses in the Peripheral Blood
and in the Sentinel Immunized Node
Immunization of HLA-A2+ Melanoma
Patients in the Adjuvant Setting with a Mutated gp100 Peptide
(209-2M) Induces Specific T Cell Immune Responses
Transduction of human dendritic
cells with a melanoma polyepitope simultaneously primes multiple
T-cell responses but ultimately results in immunodominance
Comparative Analysis of Necrotic
and Apoptotic Tumor Cells as a Source of Antigen(s) in Dendritic
Cell-Based Immunization
Pharmacogenomic Applied to
Drug Development
Directed Molecular Evolution
of Vaccines and Immunotherapeutics
Approaches for Identifying
and Accelerating the Prioritization of all the Potential Target
Genes and Therapeutic Proteins in the Genome
Classification and Diagnostic
Prediction of Cancers using Gene Expression Profiling and
Artificial Neural Networks
Clinical Proteomics: Toward
Personalized Molecular Medicine
Ranitidine as adjuvant treatment
in colorectal cancer: Influence of blood transfusion and postoperative
bacterial infections
Phase I/IB trial of the immunocytokine
hu14.18-IL2 in patients with GD2-positive tumors
Prophylactic Antitumor Efficacy
of a Combination Therapy With a Xenogeneic Cell Line Producing
Flt3-Ligand (FL),Tumor Cell Lysate, and Interleukin-2 in Mice
With Syngeneic Colon Cancer
Inhibition of tumor progression
and neoangiogenesis using cyclic RGD-peptides in a chemically
induced colon carcinoma in rats
Intratumoral Expansion of Tumor-Specific
B Cells in Invasive Ductal Carcinoma of the Breast
Signaling defects in CD8+CD27-CD45RO-
circulating effector cells in patients with cancer
CD22-DIRECTED IMMUNOTHERAPY
OF LYMPHOMA
Humanized Anti–HLA-DR
Monoclonal Antibody Hu1D10 (Remitogen) for the Treatment of
Relapsed Non-Hodgkin’s Lymphoma: A Phase I Trial
Anti-Cytotoxic T-Lymphocyte-Associated
Antigen-4 (anti-CTLA-4) Monoclonal Antibody (MDX-CTLA-4) in
Patients with Metastatic Melanoma
Early-Phase Clinical Development
of the Immunocytokine EMD 273066 (huKS-IL2): Laboratory and
Safety Findings in Patients With Prostate Cancer
Synergistic anti-tumor responses
against metastatic cancer using antibodies to CD40 and IL2:
coordination of dendritic cell and T cell arms of the immune
response
Recurrent Murine Neuroblastomas
Increase or Decrease MHC Class I Expression to Respectively
Escape NK- or T Cell-Dependent Immunotherapy
Combined Administration of
Antibodies to Human Interleukin-8 and Epidermal Growth Factor
Receptor Results in Increased Anti-metastatic Effects on Human
Breast Carcinoma Xenografts
Repopulating stem cells
carrying chemotherapy resistance-inducing genes
Clinical Results of a PSA-Selective,
Replication-Competent Adenovirus for the Treatment of Prostate
Cancer.
Vaccines for Cancer Treatment:
From Mice to Men
Differential impact of local
production interleukin-2 and interleukin-12 on initial appearance
and long-term progression of B16F10 melanoma in mice
A DNA Vaccine Encoding Genetic
Fusions of CEA and GMCSF
Systemic p53 Gene Therapy
of Cancer with Immunolipoplexes Targeted by Anti-Transferrin
Receptor scFv
Thalidomide and its Successor
Molecules as Agents for Biological Therapy
From Coley’s Toxins
to Immunotherapy with CpG DNA Motifs from Bacterial DNA
SUPPRESSION OF BCL-2 GENE
EXPRESSION BY TARGETED DISRUPTION OF RNA
ANGIOZYME, a synthetic ribozyme
targeting the mRNA of VEGFR-1: clinical update
Pharmacokinetics in beagle
dogs and cynomologus monkeys, of VNP20009, an attenuated Salmonella
typhimurium for the treatment of cancer
A Phase 2 Trial To Evaluate
the Rate of Immune Response Using Recombinant Idiotype for
Treatment of Follicular Non-Hodgkin’s Lymphoma
Shikonin, a small molecule
compound from Chinese herbal medicine with anti-inflammatory
and anti-HIV-1 activity, is an inhibitor of multiple chemokine
receptors
TRAIL Induced Apoptosis of
Human Melanoma is Regulated by Smac/DIABLO Release from Mitochondria
The proteasome inhibitor PS-341
sensitizes tumor cells to TRAIL-mediated lysis
